Overview

Safety and Efficacy of Doses of LEO 43204 Once Daily for Two Consecutive Days on Full Balding Scalp in Subjects With Actinic Keratosis

Status:
Completed
Trial end date:
2015-03-01
Target enrollment:
Participant gender:
Summary
To identify the Maximum Tolerated Dose levels of LEO 43204 after once daily treatment for two consecutive days and to evaluate efficacy of LEO 43204 in two doses after once daily treatment for two consecutive days compared to vehicle
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
LEO Pharma